Hadassah

Hadassah, Rambam, and German Triumvirate Identify Another Fatal Genetic Disease

Monday, Jun 20 2016

Molecular characterization of LAT mutation: Top=Patient; Middle=Parent; Bottom-=Unrelated healthy individual

The mystery of yet another genetic mutation that has fatal consequences for children has been unraveled by a tripartite collaboration initiated by the Hadassah Medical Organization with colleagues from the Rambam Medical Center’s Ruth Rappaport Children’s hospital in Haifa and German partners. The cooperative venture is dedicated to the discovery and characterization of congenital diseases of the immune system.

Recently, successful collaboration led to saving 15 Russian children who suffered from osteopetrosis and a Palestinian child who had Evans Syndrome through bone marrow transplantation performed at Hadassah by Dr. Polina Stepensky, head of the Pediatric Bone Marrow Transplantation Unit.

The discovery of this new gene, called a LAT signaling pathology, is the first report of an LAT-related disease in humans. (LAT dysfunction had previously been defined in mice.)  LAT, the Linker that is needed for Activation of T cells, is a critical signaling hub for a healthy, well-regulated immune system.

A child with LAT pathology suffers from a progressive combination of immune deficiency and severe autoimmune disease, as a result of the T immune cells not being activated properly.

The mutation was identified through the examination of the clinical and laboratory data of three Israeli Arab siblings from a consanguineous marriage (where the parents are relatives). All three patients suffered from recurrent infection caused by immune system deficiency, proliferation of lymph modes, and life-threatening autoimmune disease since early infancy. The first sibling was seen at age five months; the second, at six months; and the third, at ten months.

At five months, the male infant already exhibited severe anemia and lymph node and spleen abnormalities. At the age of seven, his spleen was removed. At age nine, it was deemed necessary to give him a stem cell transplant, but he passed away due to a severe infection with lung complications before he could have the transplant.

The second sibling, seen first at half a year, exhibited cerebral palsy and an abnormality in his brain, thanks to severe infection. From age one onward, he began contracting recurrent respiratory tract infections which progressed to chronic lung disease. He, too, suffered from an abnormal spleen and lymph nodes, along with other health problems. From the age of six, he was treated with steroids for severe Evans syndrome, an immune system malfunction, where the immune system destroys its own blood cells. At age seven, various infections caused the deterioration of his respiratory system. He was given antiviral and immunoglobulin therapy and improved gradually. At age eight, he received a stem cell transplant at Hadassah from his fully matched sibling and is doing well. The boy had been treated and followed at Rappaport Children’s Hospital and the treating physician, Dr. Irina Zaidman, head of the Pediatric Bone Marrow Transplant Unit there, initiated the collaboration with Hadassah when he was the single child still alive from the affected siblings.

When the third sibling, the younger sister, was seen at age 10 months, she exhibited gastroenteritis, recurrent pneumonia, and urinary tract infection. At age two, she died of anemia and thrombocytopenia (a deficiency of platelets in her blood).

As the authors explain, “All patients suffered from early onset autoimmune manifestations with normal lymphocyte counts and Ig levels. During the progression of the disease, the immune systems of the two older patients seemed to collapse, lymphocytopenia (abnormally low lymphocyte count) and hypogammaglobulinemia (primary immune deficiency) developed, and opportunistic as well as other infections occurred. The early death of patient three at two years of age probably explains why she did not enter the second phase of the disease observed in her siblings.”

Extensive biochemical and genetic analysis led the researchers to their finding that a disruption in the LAT signaling hub is the culprit.

“This is an additional example of successful collaboration among physicians (who are also friends), where we demonstrated how a precise genetic and immunological diagnosis can save the life of affected children. Our discovery can also help in the future, not only to identify additional patients, but also to understand the human immune system better.”

The study is highlighted in the May 30, 2016 issue of Journal of Experimental Medicine.

Comments

No comments yet.
First Name
Email
Comment
Enter this word:

Related Stories

alt_text

Friday, Jan 13 2017

Saving Children in the Nick of Time at Hadassah

When a four-year-old, blue and critically ill, was rushed into the pediatric emergency room at Hadassah Hospital Mount Scopus, Dr. David Rekhtman, head of the ER, and his team deciphered that the child had somehow consumed methadone.

READ MORE ›
alt_text

Friday, Jan 13 2017

Peace in Sight: An Israeli, Palestinian, and Hadassah Australia Collaboration

St. John of Jerusalem Eye Hospital, in collaboration with Hadassah Medical Center, has received a €500,000 grant from the European Union to establish a genetic research unit to serve the Palestinian communities.

READ MORE ›
alt_text

Friday, Jan 13 2017

A Second Chance at Life, Thanks to Hadassah’s Heart Institute

A resident of a rural settlement called Dishon, established by Libyan Jewish immigrants in 1953, Eyal Amar, age 47, was rather young to suffer a devastating heart attack. Nevertheless, he did, but thanks to the courage and skill of the specialists at the Hadassah Medical Organization’s Heart Institute and their complex protocol to redesign his heavily damaged heart, Eyal is able to walk and breathe again.

READ MORE ›
alt_text

Tuesday, Jan 10 2017

From Locked Jaw to Osteoarthritis: Hadassah Discovery Leads to New Treatment

What began as a solution to locked jaw--temporomandibular joint (TMJ) disorder--has led to the creation of a novel non-opioid pharmaceutical candidate for the treatment of osteoarthritis pain, thanks to a Hadassah Medical Organization discovery and collaboration with colleagues at the Hebrew University and the Technion.

READ MORE ›

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Missions Department

missions@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More